TY - JOUR
AU - C. Perry
AU - J. Liberto
AU - C. Milliken
AU - J. Burden
AU - H. Hagedorn
AU - T. Atkinson
AU - J. R. McKay
AU - L. Mooney
AU - J. Sall
AU - C. Sasson
AU - A. Saxon
AU - C. Spevak
AU - A. J. Gordon
AU - VA/DoD Guideline Development Group*
A1 - 
AB - DESCRIPTION: In August 2021, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the management of substance use disorders (SUDs). This synopsis summarizes key recommendations. METHODS: In March 2020, the VA/DoD Evidence-Based Practice Work Group assembled a team to update the 2015 VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders that included clinical stakeholders and conformed to the National Academy of Medicine's tenets for trustworthy CPGs. The guideline panel developed key questions, systematically searched and evaluated the literature, created two 1-page algorithms, and distilled 35 recommendations for care using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. This synopsis presents the recommendations that were believed to be the most clinically impactful. RECOMMENDATIONS: The scope of the CPG is broad; however, this synopsis focuses on key recommendations for the management of alcohol use disorder, use of buprenorphine in opioid use disorder, contingency management, and use of technology and telehealth to manage patients remotely.
AD - National Capital Consortium, Bethesda, Maryland (C.P.).; Office of Mental Health and Suicide Prevention, Veterans Health Administration, Washington, DC (J.L.).; Office of the Surgeon General, U.S. Army, Bethesda, Maryland (C.M.).; Office of Mental Health and Suicide Prevention, Veterans Health Administration, Salem, Virginia (J.B.).; Center for Care Delivery & Outcomes Research, Minneapolis VA Medical Center, Minneapolis, Minnesota (H.H.).; VA Tennessee Valley Healthcare System, Murfreesboro, Tennessee (T.A.).; Center of Excellence in Substance Addiction Treatment and Education, Corporal Michael J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania (J.R.M.).; VA Greater Los Angeles Healthcare System, Los Angeles, California (L.M.).; Quality and Patient Safety, Veterans Administration Central Office, Washington, DC (J.S.).; Medical Advisory Panel, VA Medical Center and Pharmacy Benefits Management, Denver, Colorado (C.S.).; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System, Seattle, Washington (A.S.).; Walter Reed National Military Medical Center, Bethesda, Maryland (C.S.).; Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS), VA Salt Lake City Healthcare System, and Program for Addiction Research, Clinical Care, Knowledge, and Advocacy (PARCKA), University of Utah, Salt Lake City, Utah (A.J.G.).
BT - Annals of Internal Medicine
C5 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
CY - United States
DO - 10.7326/M21-4011
JF - Annals of Internal Medicine
LA - eng
M1 - Journal Article
N2 - DESCRIPTION: In August 2021, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the management of substance use disorders (SUDs). This synopsis summarizes key recommendations. METHODS: In March 2020, the VA/DoD Evidence-Based Practice Work Group assembled a team to update the 2015 VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders that included clinical stakeholders and conformed to the National Academy of Medicine's tenets for trustworthy CPGs. The guideline panel developed key questions, systematically searched and evaluated the literature, created two 1-page algorithms, and distilled 35 recommendations for care using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. This synopsis presents the recommendations that were believed to be the most clinically impactful. RECOMMENDATIONS: The scope of the CPG is broad; however, this synopsis focuses on key recommendations for the management of alcohol use disorder, use of buprenorphine in opioid use disorder, contingency management, and use of technology and telehealth to manage patients remotely.
PP - United States
PY - 2022
SN - 1539-3704; 0003-4819
T1 - The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
T2 - Annals of Internal Medicine
TI - The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline
U1 - Education & Workforce; HIT & Telehealth; Opioids & Substance Use
U2 - 35313113
U3 - 10.7326/M21-4011
VO - 1539-3704; 0003-4819
Y1 - 2022
Y2 - Mar 22
ER -